Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science

Sun Yat-sen University

Status: Completed

Conditions: Biologics; Inflammatory Bowel Diseases; Crohn Disease

Study type: Observational

Funder types: Other

Identifiers

NCT05642247

2022ZSLYEC-317

Details and patient eligibility

About

Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inpatients with Crohn's disease diagnosed in the IBD center of Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022
• Treated with Ustekinumab and followed up regularly for 20 weeks
• Complete pre-treatment cross-sectional imaging data (CTE/MRE and US)

Exclusion criteria

• The diagnosis is not clear
• Under the age of 18
• Lack of endoscopic and pathological data

Trial design

150 participants in 1 patient group

CD patients who received Ustekinumab treatment

Description:

1. Inpatients with Crohn's disease diagnosed in the Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022. 2.The patients were treated with Ustekinumab and followed up regularly for 20 weeks. 3. Complete pre-treatment cross-sectional imaging data (CTE/MRE and US)